Article (Scientific journals)
Refractory hypercalcemia and ectopic calcitonin secretion in a malignant pancreatic neuroendocrine tumor: hypocalcemic effects on cinacalcet
VALDES SOCIN, Hernan Gonzalo; rubio almanza, Matilde; LOLY, Jean-Philippe et al.
2013In Acta Clinica Belgica, 68 (6), p. 42
Peer Reviewed verified by ORBi
 

Files


Full Text
Poster Cinacalcet (1).pptx
Publisher postprint (695.75 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
hypercalcemia; calcitonin; cinacalcet; sutent; neuroendocrine tumor; paraneoplastic; malignant; treatment
Abstract :
[en] Introduction: Paraneoplastic hypercalcemia is a sign of poor prognosis, as it is particularly resistant to the usual hypocalcemic treatments. Observation: In 2009, a well differentiated pancreatic neuroendocrine tumor (Ki-67= 2%) is diagnosed in a 52-year-old diabetic man. The tumor is revealed with a splenic and hepatic carcinomatosis. Plasmatic calcium was: 3.54 mmol/L (2.15 - 2.6). Biology showed hypophosphatemia, PTH < 4 ng/ml, high 1-25 OH VitD, calcitonin: 1016 ng/ml (< 12 ng/ml). He had hypercalciuria and hypophosphaturia. He received for two years several cycles of Streptozotocin-ADRIAMYCIN and FOLFOX, with partial control of the tumor mass and calcium levels. In 2012, calcitonin levels are 29 ng/ml whereas calcemia is 3.17 mmol/L. Hypercalcemia is refractory to hyperhydration, diuretics, corticosteroids, and bisphosphonates therapy. Cinacalcet (Mimpara) is prescribed up to 120 mg/day (PO). Calcemia decreases gradually from 3 to 2.87 and then 2.76 mmol/L. PTH and calcitonin-the tumor mass remain unchanged. After two months of Cinacalcet treatment, Sunitinib (Sutent) 37.5 mg per day was added. During the third month, calcium levels dropped to 2.09 mmol/L and PTH raised to 78 pg/ml, requiring discontinuation of Mimpara. Calcitonin normalized, with a further improvement over pancreatic and metastatic lesions. Conclusion: Cinacalcet is a Calcium Sensing Receptor oral agonist. Cinacalcet hypocalcemic effects have not been previously documented in pancreatic paraneoplastic hypercalcemia. In our patient, Cinacalcet has significantly improved cancer prognosis: this drug could be a new alternative in paraneoplastic hypercalcemia.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
VALDES SOCIN, Hernan Gonzalo  ;  Centre Hospitalier Universitaire de Liège - CHU > Endocrinologie clinique
rubio almanza, Matilde;  Université de Liège - ULiège > endocrinologie
LOLY, Jean-Philippe  ;  Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
POLUS, Marc ;  Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
BECKERS, Albert ;  Centre Hospitalier Universitaire de Liège - CHU > Endocrinologie clinique
Language :
English
Title :
Refractory hypercalcemia and ectopic calcitonin secretion in a malignant pancreatic neuroendocrine tumor: hypocalcemic effects on cinacalcet
Alternative titles :
[en] Hypercalcémie refractaire et secretion de calcitone ectopique dans un tumeur pancreatique neuroendocrinienne maligne: effetcs hypocalcémiants du cinacalcet
Publication date :
November 2013
Journal title :
Acta Clinica Belgica
ISSN :
0001-5512
Publisher :
Acta Clinica Belgica, Bruxelles, Belgium
Volume :
68
Issue :
6
Pages :
42
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 15 January 2014

Statistics


Number of views
182 (19 by ULiège)
Number of downloads
139 (3 by ULiège)

Bibliography


Similar publications



Contact ORBi